Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H27N |
| Molecular Weight | 293.4458 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)CN(C)C
InChI
InChIKey=ALELTFCQZDXAMQ-UHFFFAOYSA-N
InChI=1S/C21H27N/c1-16(15-22(2)3)14-21-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)21/h4-11,16,21H,12-15H2,1-3H3
| Molecular Formula | C21H27N |
| Molecular Weight | 293.4458 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1036481
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1036481
Butriptyline is a tricyclic antidepressant used in patients with depression associated with anxiety. The drug is supposed to be withdrawn from the market as the last publication about its clinical use is dated by 1988.
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
46.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6894708/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6894708/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
638.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6894708/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
536.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6894708/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6894708/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
19.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6894708/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTRIPTYLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
145 mg 1 times / day multiple, oral Studied dose Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
75 mg single, oral Studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
3425 mg single, oral Overdose |
healthy |
Disc. AE: death... AEs leading to discontinuation/dose reduction: death (grade 5, 1 pt) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| death | grade 5, 1 pt Disc. AE |
3425 mg single, oral Overdose |
healthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of butriptyline on subjective feelings and sleep. | 1977-04 |
|
| Some clinical pharmacological studies with butriptyline, an antidepressive drug. | 1977-02 |
|
| Clinical experience with butriptyline (AY-62014) in the treatment of depressions. | 1971 |
|
| Report of butriptyline hydrochloride (Evadyne) in ambulatory patients. | 1971 |
|
| Psychopharmacological evaluation of a new antidepressant: butriptyline. | 1969-12 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1036481
The daily dosage is between 75 and 150 mg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/408861
Butriptyline exhibited rather potent inhibition of 3H-dopamine uptake in rat corpus striatum with IC50 value in the range 10(-6)-10(-5) M.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:20:27 GMT 2025
by
admin
on
Mon Mar 31 18:20:27 GMT 2025
|
| Record UNII |
Z22441975X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN06AA15
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
||
|
WHO-ATC |
N06AA15
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
21772
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
19895
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000076906
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
DB09016
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
SUB13137MIG
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
Z22441975X
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
35941-65-2
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
C79855
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
455
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
m2805
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
2123
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
BUTRIPTYLINE
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110816
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY | |||
|
DTXSID6022715
Created by
admin on Mon Mar 31 18:20:27 GMT 2025 , Edited by admin on Mon Mar 31 18:20:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
TARGET -> INHIBITOR | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |